The approval also covers Keytruda SC, known in the US as Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph).

The FDA approved a new injected version of the cancer immunotherapy drug Keytruda. With injections, patients need only an hour total for treatment, while Keytruda infusion may require two hours.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that KEYTRUDA® (pembrolizumab), in ...

Merck (MRK) announced on Thursday that the European Commission approved its anti-PD-1 therapy Keytruda in combination with chemotherapy (paclitaxel) as a late-line option for certain adults with ...

Merck’s Keytruda plus paclitaxel ± bevacizumab gets EU approval to treat adults with PD-L1 platinum-resistant recurrent ovarian carcinoma who have received one or two prior systemic treatment regimens ...

(Reuters) -Gilead Sciences' Trodelvy in combination with Merck's blockbuster immunotherapy Keytruda lowered the risk of an aggressive type of breast cancer worsening by 35% when used as an initial ...

U.S. Food and Drug Administration (FDA) has approved a PD-L1 companion diagnostic test for patients with esophageal cancer or ...

Radiation therapy combined with Keytruda increased T cell infiltration in HR+ and HER2-negative breast cancer, enhancing immune response. High-dose radiation with Keytruda led to increased ...

Merck & Co.’s Keytruda has become the first immunotherapy approved by the FDA to be used around surgery to treat resectable locally advanced head and neck cancer. But the breakthrough approval comes ...

PADCEV plus KEYTRUDA is the first and only regimen to improve survival when used before and after standard of care (surgical cystectomy) in cisplatin-ineligible patients with muscle-invasive bladder ...

In final draft guidance (PDF), NICE has said that Keytruda (pembrolizumab) can be used within NHS England as a treatment for ...